Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
Alimentary Pharmacology & Therapeutics · 2024-12 · 60 (11-12) · 1525-1533
DOI: 10.1111/apt.18331 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-10-16. Written by Philip N Newsome and 9 co-authors. Institution: Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King's College London and King's College Hospital, London, UK. Major MEDLINE topics: Glucagon-Like Peptides, Non-alcoholic Fatty Liver Disease. Cited 152 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: Novo Nordisk A/S.
Abstract (original language)
Background
Semaglutide, a glucagon‐like peptide‐1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction‐associated steatohepatitis (MASH).
Aims
To describe the trial design and baseline characteristics of the ‘Effect of Semaglutide in Subjects with Non‐cirrhotic Non‐alcoholic Steatohepatitis’ (ESSENCE) trial (NCT04822181).
Methods
ESSENCE is a two‐part, phase 3, randomised, multicentre trial evaluating the effect of subcutaneous semaglutide 2.4 mg in participants with biopsy‐proven MASH and fibrosis stage 2 or 3. The primary objective of Part 1 is to demonstrate that semaglutide improves liver histology compared with placebo. The two primary endpoints are: resolution of steatohepatitis and no worsening of liver fibrosis, and improvement in liver fibrosis and no worsening of steatohepatitis. The Part 2 objective is based on clinical outcomes. The current work reports baseline characteristics of the first 800 randomised participants which includes demographics, laboratory parameters, liver histology, non‐invasive tests and presence of metabolic dysfunction‐associated steatotic liver disease (MASLD) cardiometabolic criteria.
Results
Of 800 participants, 250 (31.3%) had fibrosis stage 2 and 550 (68.8%) had fibrosis stage 3. In the overall population, mean (standard deviation [SD]) age was 56 (11.6) years, 57.1% were female, mean (SD) body mass index was 34.6 (7.2) kg/m 2 , 55.5% had type 2 diabetes and > 99% had at least one MASLD cardiometabolic criterion according to the published definition.
Conclusion
The ESSENCE baseline population includes participants with clinically significant fibrosis stages 2 and 3. Although MASLD cardiometabolic criteria were not a requirement for study enrolment, almost all participants (> 99%) had at least one MASLD cardiometabolic criterion. Trial Registration NCT04822181
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King's College London and King's College Hospital, London, UK.
- College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
- VCU School of Medicine, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Richmond, Virginia, USA.
- Novo Nordisk A/S, Copenhagen, Denmark.
- Department of Medical Sciences, University of Turin, Turin, Italy.
- Division of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, Illinois, USA.
ORCID profiles: Philip N Newsome, Arun J Sanyal, Michael Roden, Vlad Ratziu
Funding
- Novo Nordisk A/S
Cite
APA
Newsome, P. N., Sanyal, A. J., Engebretsen, K. A., Kliers, I., Østergaard, L., Vanni, D., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2024). Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Alimentary Pharmacology & Therapeutics, 60(11-12), 1525-1533. https://doi.org/10.1111/apt.18331
Vancouver
Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Østergaard L, Vanni D, et al. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Alimentary Pharmacology & Therapeutics. 2024;60(11-12):1525-1533. doi:10.1111/apt.18331
BibTeX
@article{Newsome2024,
author = {Newsome, Philip N and Sanyal, Arun J and Engebretsen, Kristiane A and Kliers, Iris and Østergaard, Laura and Vanni, Denise and Bugianesi, Elisabetta and Rinella, Mary E and Roden, Michael and Ratziu, Vlad},
title = {Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {11-12},
pages = {1525--1533},
doi = {10.1111/apt.18331}
}
EUVIMED